Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
暂无分享,去创建一个
L. Rubinstein | P. LoRusso | S. Hunsberger | S. Boerner | P. Ivy | R. Royds | Sachin Gupta
[1] J. Lee,et al. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. , 2013, Journal of the National Cancer Institute.
[2] L. Trani,et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] J Jack Lee,et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Kurzrock,et al. Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment , 2010, Clinical Cancer Research.
[5] R. Fehrmann,et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience. , 2010 .
[6] Razelle Kurzrock,et al. Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse , 2010, Clinical Cancer Research.
[7] I Judson,et al. Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? , 2009, British Journal of Cancer.
[8] R. Kurzrock,et al. Survival of patients in a Phase 1 clinic , 2009, Cancer.
[9] S. Cannistra. Challenges and pitfalls of combining targeted agents in phase I studies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] I. Haines. Dose selection in phase I studies: why we should always go for the most effective. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Kurzrock,et al. Survival of patients in a phase I clinic: The M. D. Anderson Cancer Center experience , 2008 .
[12] S. Sleijfer,et al. Dose selection in phase I studies: why we should always go for the top. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Bonneterre,et al. Prognostic factors among cancer patients with good performance status screened for phase I trials , 2008, Investigational New Drugs.
[15] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[16] H. Swaisland,et al. Development of the Novel Biologically Targeted Anticancer Agent Gefitinib , 2004, Clinical Cancer Research.
[17] Edward L Korn,et al. Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents. , 2004, Journal of the National Cancer Institute.
[18] E. Eisenhauer,et al. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.
[19] E. Emanuel,et al. Ethics of phase 1 oncology studies: reexamining the arguments and data. , 2003, JAMA.
[20] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[21] Elizabeth Fox,et al. Clinical trial design for target-based therapy. , 2002, The oncologist.
[22] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[23] D. D. Hoff,et al. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics , 1991, Investigational New Drugs.
[24] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[25] W. Pratt,et al. The Anticancer Drugs , 1979 .
[26] G. Giaccone,et al. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). , 2008, European journal of cancer.
[27] N. Magné,et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[30] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.